Sorafenib, a novel drug for metastatic renal cancer, has broadspectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and plateletderived growth factor receptor. However, little is known about its effects on the immune system. In this report, we examine the effects of sorafenib on the proliferation and activation of human peripheral blood T cells, as well as its effects on T-cell-mediated immune response in mice. At concentrations similar to those used in patients, sorafenib inhibited the proliferation of primary human T cells in vitro. At more than 10 lM, sorafenib caused an irrecoverable inhibition of proliferation, even after drug withdrawal. In addition, sorafenib induced T-cell apoptosis at concentrations higher than 10 lM. sorafenib also caused G 0 /G 1 phase arrest, inhibition of CD25 and CD69 expression, interleukin-2 production and LCK phosphorylation in the T cells; all of these effects exhibited dose and time dependence. When tested against contact dermatitis in mice, sorafenib significantly reduced the ear swelling induced by picryl chloride. These findings suggest that sorafenib may cause the loss of T-cell immune response by inducing apoptosis and targeting LCK. This could potentially lead to immunosuppression in patients with cancer.
Introduction
Sorafenib (BAY43-9006; Nexavar) is a Raf inhibitor that is used for the treatment of renal cell carcinoma (RCC), 1, 2 which has shown activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families. 1, 3 Recent studies have highlighted the significance of sorafenib in the inhibition of mutants of the tyrosine kinases in the PDGFR and Fms-like tyrosine kinase-3 receptors (FLT3), [4] [5] [6] [7] which are implicated in the pathogenesis of myeloid malignancies. 5 The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and low doses of sorafenib are effective in the treatment of FIP1L1-PDGFRA-positive CEL even in patients with resistance to imatinib, which is associated with the T674I mutation. 7 In the leukemia cell lines MV4-11 and EOL-1, the sorafenib treatment resulted in decreased cell proliferation with inhibition of FLT3 signaling. 4 Although it is clear that sorafenib inhibits the proliferation of leukemia cells, its effects on normal peripheral T cells and T-cell-mediated immune response have not been defined.
The inhibition of Ras/Raf/mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)/extracellular signalregulated kinase (ERK) pathway is one of the mechanisms known to limit the activation of T cells. 8 For example, the MEK inhibitor PD98059 and the selective MEK1 inhibitor Ro092210 can suppress anti-CD3-induced T-cell proliferation and interleukin-2 (IL-2) production. 9, 10 As a Raf inhibitor, sorafenib might have some influence on the T-cell-mediated immune response when used in patients with cancer. Of particular importance are the identification and characterization of the latent immunosuppressive effects of sorafenib in RCC therapy, because distinct features of RCC support the contention that they can be naturally recognized by the immune system. 11 Any impact on T-cell functions may not only impair the clinical efficacy of this outstanding drug, but also result in unpredictable side effects.
In general, the physiological activation of T lymphocytes in response to antigens is controlled by signaling via the T-cell receptor (TCR). 12 Upon engagement of the TCR by the antigen presented on the major histocompatibility complex, the Src family kinase LCK is activated. It then proceeds to phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAMs) on the signaling subunits e, d, g and z of the TCR-CD3 complex to recruit and activate ZAP-70. Two known substrates of ZAP-70, LAT and SLP-76, then recruit a number of other proteins involved in the Ras pathway for activation. These events lead to the activation of the mitogen-activated protein kinases (MAPKs) ERK, JNK and P38. 13 The functional consequences of T-cell activation include the proliferation, cytokine production and upregulation of activation markers such as CD25 and CD69. 14 The aim of this study is to determine whether sorafenib influences normal T cells for reference in clinical use. We show here that sorafenib significantly inhibits human peripheral blood T-cell proliferation and activation in vitro, and reduces the immune response mediated by T cells in mice. The sorafenib-induced blockade of cell cycle progression proved to be the result of the unique targeting of LCK phosphorylation in the TCR signaling.
Materials and methods

Animals
Female BALB/c and DO11.10 mice (6-8 weeks old, 18-22 g) were supplied by the Model Animal Genetics Research Center (Nanjing, China). They were maintained in specific pathogenfree condition at 25 ± 2 1C and kept on a 12-h light-dark cycle. Animal welfare and experimental procedures were carried out strictly in accordance with the Guide for the Care and Use of Laboratory Animals (The Ministry of Science and Technology of China, 2006) and the related ethical regulations of our university. All efforts were made to minimize the animals' suffering and to reduce the number of animals used.
Cells and reagents
Peripheral blood mononuclear cells (PBMCs), collected from normal healthy volunteer donors, were purified by Ficoll density gradient centrifugation. Normal human T cells were enriched from PBMCs by R&D Systems' Human T-Cell Enrichment Columns (R&D, Minneapolis, MN, USA). The purification rate of CD3 þ T cells was 90±5%. Mouse CD4 þ T cells were isolated using magnetic beads (Miltenyi Biotec, Auburn, CA, USA) with more than 95% purification. The cells were incubated in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% newborn calf serum (NBS), in a humidified atmosphere of 5.0% CO 2 at 37 1C. Human acute leukemia T-cell line Jurkat cells (colon E6-1) were obtained from the Institute of Biochemistry and Cell Biology (Shanghai, China) and cultured under the same conditions. Sorafenib (Bayer, Leverkusen, Germany) was dissolved in dimethyl sulfoxide to a concentration of 20 mM as stock solution, which was stored at À20 1C until use. Phytohemagglutinin (PHA), pertussis toxin (PTX) and staphylococcal enterotoxin B (SEB) were obtained from Sigma (St Louis, MO, USA).
CFSE proliferation assay
Purified human PBMCs (1 Â 10 7 cells per ml) were suspended in phosphate-buffered saline containing 0.1% bovine serum albumin and labeled with the vital dye carboxyfluorescein diacetate succinimidyl ester (CFSE) at a final concentration of 2.5 mM for 10 min at 37 1C. After labeling, the cells were washed three times in NBS-rich medium and resuspended in RPMI 1640 medium (2.5 Â 10 6 cells per ml). The CFSE-labeled cells were preincubated with sorafenib for 1 h as indicated, and then cultured for 96 h in the presence of 5 mg ml À1 PHA.
MTS proliferation assay
The cell viability was assessed by the bioreduction of a tetrazolium compound (Promega MTS assay kit; Promega, Madison, WI, USA) by measuring absorbance at 492 nm in a 96-well plate reader. The stimulation index was calculated as the absorption in drug-treated samples divided by that in drugnontreated samples.
Apoptosis assay
Human blood T cells (5 Â 10 5 cells per well in 200 ml medium) were stimulated with 5 mg ml À1 PHA in the presence of various concentrations of sorafenib for 48 h and stained with both Annexin V-FITC (fluorescein isothiocyanate) and propidium iodide (PI). Activity of caspase 3 was measured by CaspGLOW Fluorescein Active Caspase-3 Staining Kit (Bio Vision, CA, USA).
IL-2 assay
Human blood T cells (1 Â 10 5 cells per well) were cultured in 96-well plates with or without sorafenib for 24 h, in the presence or absence of 5 mg ml À1 PHA. IL-2 production was measured with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Biosource, Camarillo, CA, USA) according to the manufacturer's instructions.
Protein phosphorylation analysis by western blotting
Western blotting analysis was performed as described previously. 15 Monoclonal antibodies (mAb) specific for 
Adoptive transfer and immunization
The protocol for the adoptive transfer of DO11.10 T cells was slightly modified from the previously described method. 16 Briefly, splenocytes from DO11.10 donor mice were harvested and pooled. Then, the CD4 þ T cells were separated and labeled with CFSE. An aliquot of cells containing 2.5 Â 10 6 CD4 þ T cells was i.v. injected into an age-and sex-matched BALB/c mouse. Adoptively transferred mice were rested for 3 days and then immunized with 150 mg OVA 323-339 peptide (Genscript, NJ, USA) emulsified in CFA (Sigma) via s.c. injection at two dorsal sites on the back. Then the lymph nodes were harvested. Living cells were subsequently counted and stained with anti-CD4-phycoerythrin (PE) antibody. The percentage of dividing T cells was calculated as the percentages of gated cells divided by the percentages of CFSE þ cells.
Picryl chloride-induced contact hypersensitivity
Mice were sensitized by painting 100 ml of 1% picryl chloride (Wako, Osaka, Japan) in ethanol onto the shaved skin of their abdomens. Five days after sensitization, they were challenged on the right ear with the painting of 30 ml of 1% picryl chloride in olive oil. Ear swelling was evaluated by the difference in thickness between the right and left ears, as measured with an engineer's micrometer 24 h after the challenge. The swellingnegative group was normally sensitized and painted with the vehicle olive oil when challenged. The control animals with contact hypersensitivity were given saline instead of drugs.
Histological analysis
Formalin-fixed, paraffin-embedded mouse ear tissues were sectioned at 5 mm in thickness, and the sections were stained with hematoxylin and eosin. Histopathologic scoring was carried out by using a range from 0 (no change) to 4 (most severe) to evaluate congestion, edema and inflammatory cell infiltration and so on.
Statistics
All experiments were repeated 3-5 times with the similar outcome. The P-values between two experimental groups were tested by two-tailed Student's t-test. The level of significance was set at a P-value of 0.05. Where applicable, data were reported as the mean±s.d.
Results
Sorafenib inhibits the proliferation of human peripheral blood T cells in a dose-dependent manner
As shown in Figure 1a , sorafenib inhibited T-cells proliferation induced by PHA in a concentration-dependent manner: more than 70% at 5 mM and almost completely at 10 mM. Total cell numbers were also counted using the MTS assay and a dosedependent reduction was found in total number of PBMCs ( Figure 1b ). It should be noted that the maximum concentration of sorafenib was more than 15 mM in the serum of patients receiving 400 mg b.i.d. 17 Subsequently, we determined whether sorafenib could terminate proliferation signals that had been initiated. The CFSE-labeled cells were stimulated with PHA for 96 h. During the incubation, 10 mM of sorafenib was added at either 12, 24 or 36 h after the PHA stimulation. PHA stimulated 48.5% of CD3 þ T cells to divide, and this division was markedly reduced by 71.3, 67.8 and 38.1% with to the addition of sorafenib at 12, 24 or 36 h, respectively (Figure 1c) .
In addition, with anti-CD3/28 antibodies-, PTX-or SEBinduced proliferation of human blood T cells, sorafenib also showed concentration-dependent inhibition (Figure 1d ).
Sorafenib suppresses OVA 323-339 -specific CD4 þ T-cell response both in vitro and in vivo DO11.10 transgenic mice, with BALB/c background, were used to examine the effect of sorafenib on the response of CD4 þ T cells, specific for the peptides OVA 323-339 , because more than 90% of the TCR in the T cells of the mice can recognize the OVA 323-339 peptide. CD4 þ T cells from DO11.10 transgenic mice were stimulated by OVA 323À339 -loaded spleen cells from BALB/c in the presence and absence of sorafenib. The results were similar to those of the PHA-induced human peripheral T-cell proliferation experiment (Figure 2a ). When the OVA peptide was used to immunize BALB/c mice that had been transferred with donor CD4 þ T cells from DO11.10 mice, the p.o. administration of sorafenib at 80 mg per kg significantly reduced the percentage of dividing CD4 þ T cells in lymph nodes (Figures 2b and c) .
Higher doses of sorafenib cause an irrecoverable inhibition of proliferation, even after drug withdrawal, linked to the induction of apoptosis PBMCs were incubated with and without sorafenib for 12 h. After the removal of sorafenib, the cells were incubated with PHA for additional 96 h. At concentrations of 1 and 5 mM, the sorafenib pretreated T cells remained proliferated after PHA. However, at more than 10 mM, the cells did not recover from the inhibited proliferation and there was no dividing T-cell population at 96 h after the withdrawal of 20 mM sorafenib (Figure 3a) .
To examine the relationship of this finding to apoptosis, we incubated T cells with sorafenib in the presence and absence of PHA for 24, 48, 72 and 96 h. At concentrations lower than 10 mM, sorafenib neither influenced the apoptotic cell counts nor the caspase 3 activity, relative to the untreated cells. However, cell apoptosis was detected when concentrations higher than 10 mM were used. Figures 3b and c show the data at 48 h; the cells were stained with Annexin V and PI and with FITC-DEVD-FMK. Moreover, Jurkat cells were incubated with sorafenib for 48 h. In contrast to normal T cells, at concentrations below 10 mM, sorafenib reduced the proliferation of Jurkat cells in a dose-dependent manner; this was accompanied by an increase Sorafenib causes human blood T-cell arrest in the G 0 /G 1 phase of the cell cycle
As shown in Figure 4a , T cells isolated from healthy volunteer were initially resting in the G 0 /G 1 phase of the cycle. PHA (5 mg ml À1 ) stimulation resulted in the progression into the S phase and notable DNA synthesis. Against this progression, sorafenib showed an efficient inhibition. Furthermore, sorafenib inhibited the T-cell cycle progression even under conditions of increased DNA synthesis in the co-presence of PHA (10 mg ml À1 ) and IL-2 (500 U ml À1 ) (Figure 4a) . A requirement of entry into the S phase is the phosphorylation of the retinoblastoma protein (Rb), which is regulated by the cyclin D3/CDK4/6 complex. The levels of cyclin D3 and cyclin D1 proteins along with the phosphorylation of Rb, P27 and CDK6 were examined in the presence and absence of 10 mM sorafenib by western blotting. At 24, 48 and 72 h after the addition of PHA, the amounts of cyclin D3 and Rb phosphoproteins were notably reduced. The drug also decreased the amount of the phosphoprotein CDK6, while not affecting the levels of cyclin D1 and P27. In addition, sorafenib increased the phosphorylation of CDC2, which has been known to regulate the G 2 /M phase (Figure 4b ).
Sorafenib decreases CD25 & CD69 expressions and IL-2 production in human T cells
As shown in Figure 5a , the PHA treatment increased the expression of CD25 and CD69 in the anti-CD3-PE/Cy5-labeled T cells of PBMCs. Sorafenib was able to counteract the effect of the PHA in a dose-dependent manner. At the same time, the IL-2 levels in the cell culture supernatant decreased, 24 h after 5 mg ml À1 PHA stimulation (Figure 5b ).
Sorafenib inhibits Raf/MEK/ERK signaling and LCK phosphorylation involved in T-cell activation
In regard to effects on the MAPK pathway in human T-cells simulated by PHA, sorafenib just about completely inhibited ERK phosphorylation, but had no effect on P38 and JNK (Figure 6a ). To determine whether sorafenib inhibits the TCR signal transduction, we examined ZAP70 phosphorylation and found that sorafenib remarkably reduced Tyr319 phosphorylation (Figure 6a ) without affecting the levels of the ZAP-70 protein. Figure 6b shows that LCK shares more homology than ZAP70 in the ATP-binding domain with Raf, VEGFR and PDGFR. Given that ZAP70 is directly phosphorylated by the activated LCK, both PHA and anti-CD3/CD28 were respectively used to stimulate the T cells. Sorafenib inhibited the phosphorylation of LCK and ZAP70 in both scenarios (Figure 6c ). Furthermore, murine CD4 þ T cells were separated with 495% purification. After 1 h incubation with and without 10 mM sorafenib, the cells were stimulated with anti-CD3/CD28. The western blotting results were consistent with those shown in Figure 6c (Figure 6d ).
Sorafenib inhibits picryl chloride-induced delayed-type hypersensitivity in mice
Swelling of the right ear was monitored for changes occurring as a result of the systemic treatment with sorafenib, which showed Sorafenib inhibits T-cell activation W Zhao et al a significant reduction of the swelling in a dose-dependant fashion (Figure 7a) . The histopathologic changes, in the ears of the mice in the control group, were mainly observed in the dermis as severe inflammatory infiltration, vascular congestion and moderate edema. Compared to the control group, the mice treated with sorafenib only showed a mild cellular infiltration and vasodilatation without edema. cyclosporine A (CsA) also alleviated the tissue damage (Figure 7b ).
Discussion
The adverse effects of sorafenib such as hand-foot syndrome, hypertension, skin discoloration, diarrhea and fatigue have been well demonstrated. 18 However, little is known about the effects of sorafenib on T-cell proliferation and activation, which are associated with the long-term use of the drug and the prognosis of RCC. In our studies we have found that PHA-induced human blood T-cell proliferation was inhibited by sorafenib at 10 mM (Figures 1a-c) , which falls within the range of the drug concentrations in the serum of patients treated with the standard therapeutic dose of 400 mg taken twice daily. 17 In addition to mitogen, anti-CD3/CD28 antibodies as well as bacterial antigens PTX and SEB were also used to stimulate T cells. Under all of these conditions, sorafenib was able to inhibit the T-cell proliferation in a dose-dependent manner (Figure 1d) . Furthermore, the OVA-specific CD4 þ T-cell response was also inhibited in vitro and in vivo (Figure 2 ). These findings suggest that sorafenib is able to reliably inhibit the T-cell response and imply a clinical risk for its long-term administration.
We have also examined the relationship between the sorafenib-induced inhibition of T-cell proliferation and the 
Sorafenib inhibits T-cell activation
W Zhao et al induction of apoptosis. The connection was confirmed at doses higher than 10 mM (Figures 3b and c) ; at lower doses of sorafenib there was no induction of apoptosis, and recovery from the state of inhibited proliferation was achieved after the withdrawal of the drug (Figure 3a) . However, apoptosis was observed at more than 10 mM of sorafenib (Figures 3b and c) , in the meanwhile the cells lost their dividing potential at this concentration. The results obtained here not only suggest that sorafenib might function through a distinct pathway, separate from the one in leukemia cells where it showed antiproliferative activity via apoptosis at even lower doses (Supplementary Figure 1) , but also highlight the importance of dosage control for sorafenib in the clinical treatment of RCC patients. A recent phase II trial of sorafenib in patients with metastatic renal cell cancer (MRCC) revealed a requirement of dose escalation to 600 mg b.i.d. or even 800 mg b.i.d. for getting better antitumor activity of this drug. 19 However, our findings in the present study imply that such a high dose of sorafenib leads to unrecoverable immunosuppression and that the dose-escalated strategy is risky for the long-term treatment of MRCC.
The mechanism of T-cell inhibition can be construed from sorafenib's influence on cell cycle progression: a marked decrease in the proportion of S phase and G 2 /M phase cells was observed after 96 h of drug treatment (Figure 4a ). In this case, sorafenib reduced the amount of cyclin D3 and diminished the phosphorylation of CDK6, which kept Rb combining with E2F (Figure 4b ). These effects explain the arrest of the G 0 /G 1 phase of the cell cycle (Figure 4a) , which implied that function of T cells could be regained after withdrawal of sorafenib (Figure 2a) , and the increase in proliferative cells at 36 h compared to 24 and 12 h (Figure 1c) .
The Raf/MEK/ERK signaling pathway is an important mediator of tumor cell proliferation. 20 Ras is also activated by a rapid and sustained response of the TCR. Ras signaling continues to be essential for antigen-receptor function, with the loss of Ras function preventing antigen-receptor activation of proliferation and cytokine gene induction. sorafenib has been reported to target this pathway in tumor cells, thus we next turned our focus to the phosphorylation of MAPK and found that sorafenib decreased the phosphorylation of ERK in PBMCs stimulated by PHA (Figure 6a ). Little change in P38 and JNK phosphorylation was observed, suggesting that the suppression of T-cell activation by sorafenib was at least in part the result of the inhibition on the phosphorylation of ERK. The effects of sorafenib on cell activation might be explained by the inhibition of early signaling events, mediated by the receptor tyrosine kinase, or by a more global inhibition of cellular functions, downstream of the initial signaling events. In an attempt to identify the intracellular pathways targeted by sorafenib in T cells, we examined the TCR-associated phosphorylation of ITAMs. In T-cell activation, ITAMs are phosphorylated by LCK and thus promote the recruitment of ZAP70 along with its phosphorylation, which is a crucial event in TCR signaling. In the present study, we have observed that sorafenib reduced the phosphorylation of ZAP70 (Figure 6a ), which could explain the reduction in T-cell function. However, ZAP70 is an unlikely target of sorafenib because its ATP-binding pocket is not well conserved (Figure 6b ). On the other hand, the ATPbinding pocket of LCK closely resembles that of PDGFR and KIT (other known targets of sorafenib) and it is the first tyrosine kinase activated upon TCR engagement and ITAM phosphorylation. We exposed stimulated T cells to sorafenib and found that the drug inhibited the phosphorylation of LCK. From these results, we conclude that a possible mechanism explaining sorafenib's effects on T-cell activation is the inhibition of LCK phosphorylation, ITAM phosphorylation and ZAP70 recruitment. Escudier et al. 21 reported that sorafenib plus interferon-a-treated patients did not show significant changes in proangiogenic cytokines and phosphorylated extracellular signal-regulated kinases in T cells. We found that the drug suppressed cytokines production ( Figure 5b ) and some kinases phosphrylation in vitro. It should be noted that the T cells were 
W Zhao et al not stimulated by antigens in Escudier's study. Without antigen stimulation, the inhibition of kinases phosphrylation in TCR signaling could not be found in human peripheral T cells. Therefore our results do not contradict the previous studies. Delayed-type hypersensitivity (DTH) is typically used for the evaluation of in vivo immunocompetency because it has been shown to be entirely dependent on the effects of T cells. To determine if sorafenib affects T cells in vivo in the same manner it does in vitro, we used a picryl chloride-induced contact sensitivity model of DTH and treated the mice with sorafenib. Sorafenib showed a significant inhibition of the swelling in the right ear controls (Figure 7 ). Given that sorafenib was approved for use in metastatic renal cancer, which can be naturally recognized by the immune system, the immunosuppressive activity of sorafenib in the murine DTH model poses the possibility of an induced immunosuppressive state in clinical use. Such consequence should be well addressed in the evaluation of the clinical efficacy of this drug. Dr Gu has observed in her clinical work that the CD4 þ :CD8 þ ratio of T-cells decreased in patients given sorafenib therapy (Supplementary Table 1 ); this observation implies immunosuppressive activity, as described by our work. The balance between the immunosuppression of sorafenib and its anticancer efficacy should be investigated in future clinical trials.
Conclusion
The novel dosage-dependent sorafenib inhibition of the T-cellmediated immune response has been presented in this article, with focus on the proliferation and activation of human peripherally blood T cells. The underlying signaling pathway includes a reduction in LCK activity, ITAMs phosphorylation and inhibition of the ERK pathway. These effects along with the induction of apoptosis in the T-cell population lead to the suppression of T-cell activation and cell cycle arrest. This may influence the clinical use of this outstanding drug and the prognosis of patients with cancer, in particular those with RCC.
